CCR5 and infection: First, we measured the activity of FD016 in inhibiting HIV-1 laboratory-adapted strains IIIB and Bal, using AMD3100, a CXCR4 antagonist, and Maraviroc, a CCR5 antagonist, as positive controls for inhibition of IIIB and Bal infection, respectively.